The burden of migraine in Mexico: a database analysis of migraine-related visits to emergency departments in Mexico's Ministry of Health (MMoH) hospitals.

IF 3.4 2区医学 Q2 CLINICAL NEUROLOGY

Expert Review of Neurotherapeutics Pub Date : 2025-04-01 Epub Date: 2025-03-12 DOI:10.1080/14737175.2025.2474557

Luis Arturo Sanchez Trujillo, Martha Eugenia Pastrana, Javier Andres Galnares Olalde, Alejandro Marfil, Luis Roberto Partida Medina, Manuel Gudiño Castelazo, Mariana Osorio-Hernandez, Nohemi Caballero, Guilherme Silva Julian

{"title":"The burden of migraine in Mexico: a database analysis of migraine-related visits to emergency departments in Mexico's Ministry of Health (MMoH) hospitals.","authors":"Luis Arturo Sanchez Trujillo, Martha Eugenia Pastrana, Javier Andres Galnares Olalde, Alejandro Marfil, Luis Roberto Partida Medina, Manuel Gudiño Castelazo, Mariana Osorio-Hernandez, Nohemi Caballero, Guilherme Silva Julian","doi":"10.1080/14737175.2025.2474557","DOIUrl":null,"url":null,"abstract":"Background: The burden of migraine in Mexican Emergency Department (ED) settings remains understudied. This study aimed to determine the frequency of migraine-related ED visits within the ED Mexican Ministry of Health's (MMoH) database and analyze their demographics and treatment patterns.Research design and methods: This retrospective study analyzed MMoH database of ED visits between 2013 and 2022. Visits with migraine diagnosis were selected using ICD-10 codes. Demographic characteristics, geographical location, and time of consultation were described, medication use patterns were analyzed.Results: Between 2013 and 2022, there were 1,022,450 reported ED visits related to primary headache (0.6% of all ED visits), there were 179,618 migraine-related ED visits (19% of all headache visits). Females represented 78% of visits. Visits peaked in 2014 (20,066) and were the lowest in 2019 (8,273). Medication was used in 21% of visits, NSAIDs being the most frequent (15%). Triptan use was low (0.04% of all migraine visits).Conclusion: Our results highlight the significant burden of migraines on Mexico's healthcare system and the importance of considering age and sex in the approach to migraine ED visits. An update in therapeutic strategies for migraine in Mexico is needed to improve patient outcomes.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"491-500"},"PeriodicalIF":3.4000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Neurotherapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737175.2025.2474557","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/12 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The burden of migraine in Mexican Emergency Department (ED) settings remains understudied. This study aimed to determine the frequency of migraine-related ED visits within the ED Mexican Ministry of Health's (MMoH) database and analyze their demographics and treatment patterns.

Research design and methods: This retrospective study analyzed MMoH database of ED visits between 2013 and 2022. Visits with migraine diagnosis were selected using ICD-10 codes. Demographic characteristics, geographical location, and time of consultation were described, medication use patterns were analyzed.

Results: Between 2013 and 2022, there were 1,022,450 reported ED visits related to primary headache (0.6% of all ED visits), there were 179,618 migraine-related ED visits (19% of all headache visits). Females represented 78% of visits. Visits peaked in 2014 (20,066) and were the lowest in 2019 (8,273). Medication was used in 21% of visits, NSAIDs being the most frequent (15%). Triptan use was low (0.04% of all migraine visits).

Conclusion: Our results highlight the significant burden of migraines on Mexico's healthcare system and the importance of considering age and sex in the approach to migraine ED visits. An update in therapeutic strategies for migraine in Mexico is needed to improve patient outcomes.

查看原文本刊更多论文

墨西哥偏头痛的负担：墨西哥卫生部（MMoH）医院急诊室偏头痛相关访问的数据库分析。

背景：在墨西哥急诊科（ED）设置偏头痛的负担仍未充分研究。本研究旨在确定墨西哥卫生部ED （MMoH）数据库中偏头痛相关ED就诊的频率，并分析其人口统计数据和治疗模式。研究设计与方法：本研究回顾性分析了2013 - 2022年MMoH的ED就诊数据库。使用ICD-10代码选择诊断为偏头痛的患者。描述人口统计学特征、地理位置和就诊时间，分析用药模式。结果：2013年至2022年期间，有1,022,450例与原发性头痛相关的ED就诊（占所有ED就诊的0.6%），有179,618例与偏头痛相关的ED就诊（占所有头痛就诊的19%）。女性占访问人数的78%。参观人数在2014年达到顶峰（20,066人），在2019年最低（8,273人）。21%的患者使用药物治疗，其中非甾体抗炎药最为常见（15%）。曲坦类药物的使用率很低（占所有偏头痛患者的0.04%）。结论：我们的研究结果强调了偏头痛对墨西哥医疗保健系统的重大负担，以及在偏头痛急诊科就诊方法中考虑年龄和性别的重要性。墨西哥需要更新偏头痛的治疗策略，以改善患者的预后。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Neurotherapeutics Medicine-Neurology (clinical)

CiteScore

7.00

自引率

2.30%

发文量

审稿时长

4-8 weeks

期刊介绍： Expert Review of Neurotherapeutics (ISSN 1473-7175) provides expert reviews on the use of drugs and medicines in clinical neurology and neuropsychiatry. Coverage includes disease management, new medicines and drugs in neurology, therapeutic indications, diagnostics, medical treatment guidelines and neurological diseases such as stroke, epilepsy, Alzheimer''s and Parkinson''s. Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections: Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points